musculoskeletal pain epidemiology forecast insight

DelveInsight’s ‘Musculoskeletal Pain – Epidemiology Forecast – 2034’ report delivers an in-depth understanding of the historical and forecasted epidemiology of Musculoskeletal Pain in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2021-2034

Musculoskeletal Pain: Disease Understanding

Musculoskeletal Pain Overview

Musculoskeletal pain (MSP) is defined as acute or chronic pain that affects bones, muscles, ligaments, tendons, and even nerves. Musculoskeletal pain (in particular, low back pain) is the main contributor to disability worldwide. According to the World Health Organization (WHO), 20–33% of the world’s population has some form of Musculoskeletal Pain, translating to 1.75 billion people globally.

Chronic pain is a complex, multifaceted phenomenon without a widely accepted definition. It has been defined as unremitting pain lasting >3 months or simply as “pain that extends beyond an expected period of healing.” The Pain Task Force of the (IASP) defines Chronic Primary Musculoskeletal Pain (CPMP) as “chronic pain” in the muscles, bones, joints, or tendons that are characterized by significant emotional distress (i.e., anxiety, anger, frustration, and depressed mood) or functional disability. Chronic low back pain, neck pain, and hip pain are the most common types, while disorders such as hip and knee osteoarthritis and fibromyalgia are characterized by Musculoskeletal Pain.

Musculoskeletal pain is not purely nociceptive; peripheral inflammation, central sensitization processes, and neuropathic components also contribute.

NSAIDs are among the drugs most frequently recommended by orthopedic surgeons. NSAIDs and aspirin have analgesic, anti-inflammatory, and antipyretic properties and inhibit cyclooxygenase (COX). Acetaminophen has similar analgesic and antipyretic properties but lacks comparable anti-inflammatory effects. Although evidence indicates that these drugs have modest analgesic efficacy for acute musculoskeletal pain, they are markedly less effective for managing chronic pain conditions. The analgesic effects of NSAIDs and aspirin are related closely to their ability to decrease local inflammatory mediators.

In a large meta-analysis on the use of NSAIDs for lower back pain (LBP), the authors found that NSAIDs provided no greater relief of LBP than placebo. However, in clinical practice guidelines on the treatment of symptomatic osteoarthritis of the knee developed by the American Academy of Orthopedic Surgeons, selective, nonselective, and topical NSAIDs were recommended. Despite mixed evidence for the use of NSAIDs for chronic pain, many patients continue taking either prescribed or over-the-counter NSAID preparations. Prolonged use of these medications has been associated with adverse effects such as gastrointestinal (GI) complications, which both providers and patients recognize.

Morphine, the archetypal opiate, has often been considered the standard of care for analgesic management of pain. Despite the efficacy of morphine and its opioid analogs in the acute setting, these drugs generally have poor efficacy in the chronic pain setting. Gabapentin and pregabalin effectively treat patients with neuropathic pain and are approved in the United States for neuropathic pain conditions like spinal cord injury, shingles, and diabetic neuropathy. These medications have a more tolerable side-effect profile compared to other anticonvulsants. Tricyclic antidepressants (TCA) (e.g., amitriptyline and nortriptyline) have an analgesic effect independent of their antidepressant effect. The pharmacological actions of TCAs can be linked to their effect as a calcium channel antagonist, sodium channel antagonist, and their NMDA receptor antagonist effect. More specifically, the analgesic effect is believed to be due to the presynaptic reuptake inhibition of the monoamines such as serotonin and norepinephrine. Serotonin-norepinephrine reuptake inhibitors (SNRIs) (e.g., duloxetine 60–120 mg) should be considered to treat patients with various chronic pain conditions such as diabetic neuropathic pain, fibromyalgia, osteoarthritis, and LBP. Selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine (20–80 mg) may also be considered to treat patients with fibromyalgia, although it has not been successful in treating several forms of neuropathic pain.

Companies such as Mesoblast, Mitsubishi Tanabe Pharma, Regeneron Pharmaceuticals, Ampio Pharmaceuticals, Charleston Laboratories, Sorrento Therapeutics, Centrexion Therapeutics, MDM S.p.A., Braeburn Pharmaceuticals, and Taiwan Liposome Company are actively involved in developing therapies for the treatment of MSP.  It is anticipated that with the launch of key assets like Ampion (Ampio Pharmaceuticals), CAM2038 (Braeburn Pharmaceuticals), CNTX-4975 (Centrexion Therapeutics), and fasinumab, the market size would witness expedited growth during the forecasted period.

Musculoskeletal Pain: Epidemiology

The Musculoskeletal Pain epidemiology division provides insights into the historical and current patient pool, along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool, trends, and assumptions.

Key Findings

The disease epidemiology covered in the report provides historical and forecasted Musculoskeletal Pain epidemiology segmented as the Diagnosed Prevalent cases of Musculoskeletal Pain, Age-specific cases of Musculoskeletal Pain, and Gender-specific cases of Musculoskeletal Pain. The report includes the prevalent scenario of Musculoskeletal Pain in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2021 to 2034.

Country-wise Musculoskeletal Pain Epidemiology

The epidemiology segment also provides the Musculoskeletal Pain epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

• The total diagnosed prevalent population of Musculoskeletal Pain in the 7MM countries was estimated to be 145,426,730 cases in 2020.
• As per the estimates, the United States had the largest diagnosed prevalence of Musculoskeletal Pain in 2020. Among the EU5 countries, France had the largest diagnosed prevalent population of Musculoskeletal Pain with 12,649,387 cases, followed by Italy in 2020. On the other hand, Germany had the lowest diagnosed prevalent population with 8,642,397 cases in 2020.

Scope of the Report

• Musculoskeletal Pain report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.
• Musculoskeletal Pain Epidemiology Report and Model provide an overview of the risk factors and global Musculoskeletal Pain trends in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
• The report provides insight into the historical and forecasted patient pool of Musculoskeletal Pain in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
• The report helps recognize the growth opportunities in the 7MM concerning the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of Musculoskeletal Pain.
• The report provides the segmentation of the Musculoskeletal Pain epidemiology by diagnosed prevalent cases of Musculoskeletal Pain in the 7MM.
• The report provides the segmentation of the Musculoskeletal Pain epidemiology by the age-specific cases of Musculoskeletal Pain in the 7MM
• The report provides the segmentation of the Musculoskeletal Pain epidemiology by the gender-specific cases of Musculoskeletal Pain in the 7MM.

Report Highlights

• 10-year Forecast of Musculoskeletal Pain epidemiology
• 7MM Coverage
• Diagnosed Prevalent cases of Musculoskeletal Pain
• Age-specific cases of Musculoskeletal Pain
• Gender-specific cases of Musculoskeletal Pain

KOL Views

We interview KOLs and obtain SME’s opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM for the patient population pertaining to Musculoskeletal Pain?
• What are the key findings pertaining to the Musculoskeletal Pain epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2021-2034)?
• What would be the total number of patients with Musculoskeletal Pain across the 7MM during the forecast period (2021-2034)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2021-2034)?
• At what CAGR the patient population is expected to grow by 7MM during the forecast period (2021-2034)?
• What are the disease risk, burdens, and unmet needs of Musculoskeletal Pain?
• What are the currently available treatments for Musculoskeletal Pain?

Reasons to buy

Musculoskeletal Pain Epidemiology report will allow the user to:

• Develop business strategies by understanding the trends shaping and driving the global Musculoskeletal Pain market
• Quantify patient populations in the global Musculoskeletal Pain market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Musculoskeletal Pain therapeutics in each of the markets covered
• Understand the magnitude of the Musculoskeletal Pain population by its diagnosed prevalent cases of Musculoskeletal Pain
• Understand the magnitude of the Musculoskeletal Pain population by its age-specific cases of Musculoskeletal Pain.
• Understand the magnitude of the Musculoskeletal Pain population by its gender-specific cases of Musculoskeletal Pain.
• The Musculoskeletal Pain epidemiology report and model were written and developed by Masters and PhD level epidemiologists
• The Musculoskeletal Pain Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population